Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rogier Thurlings

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2018
[Pneumocystis prophylaxis during glucocorticoid use?]Quirijn de Mast, Rogier Thurlings, Jaap Ten Oever
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 16, 2024
Circulating tRNA-derived fragments are decreased in patients with rheumatoid arthritis and increased in patients with psoriatic arthritisMarina Dunaeva, Jan Blom, Rogier Thurlings, et al.
Plos One|July 2, 2010
The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritisJohan Lindberg, Carla A Wijbrandts, Lisa G van Baarsen, et al.
Nuclear Medicine and Biology|November 14, 2007
Labeling of autologous monocytes with 99mTc-HMPAO at very high specific radioactivityFormijn J van Hemert, Rogier Thurlings, Serge E Dohmen, et al.
Rheumatology (Oxford, England)|April 27, 2013
Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patientsMaria Boumans, Onno Teng, Rogier Thurlings, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
RMD Open|April 10, 2024
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trialNathan den Broeder, Lise Verhoef, Yaël A de Man, et al.
Arthritis Research & Therapy|December 21, 2018
Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy GroupsAurélie Najm, Benoît Le Goff, Carl Orr, et al.
Arthritis Research & Therapy|December 5, 2018
Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy GroupsAurélie Najm, Benoît Le Goff, Carl Orr, et al.
Nature Reviews. Rheumatology|July 14, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2018
[Pneumocystis prophylaxis during glucocorticoid use?]Quirijn de Mast, Rogier Thurlings, Jaap Ten Oever
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 16, 2024
Circulating tRNA-derived fragments are decreased in patients with rheumatoid arthritis and increased in patients with psoriatic arthritisMarina Dunaeva, Jan Blom, Rogier Thurlings, et al.
Plos One|July 2, 2010
The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritisJohan Lindberg, Carla A Wijbrandts, Lisa G van Baarsen, et al.
Nuclear Medicine and Biology|November 14, 2007
Labeling of autologous monocytes with 99mTc-HMPAO at very high specific radioactivityFormijn J van Hemert, Rogier Thurlings, Serge E Dohmen, et al.
Rheumatology (Oxford, England)|April 27, 2013
Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patientsMaria Boumans, Onno Teng, Rogier Thurlings, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
RMD Open|April 10, 2024
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trialNathan den Broeder, Lise Verhoef, Yaël A de Man, et al.
Arthritis Research & Therapy|December 21, 2018
Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy GroupsAurélie Najm, Benoît Le Goff, Carl Orr, et al.
Arthritis Research & Therapy|December 5, 2018
Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy GroupsAurélie Najm, Benoît Le Goff, Carl Orr, et al.
Nature Reviews. Rheumatology|July 14, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.
Pageof 2